EnteroMedics USA Zulassung - 500 Beiträge pro Seite

[asuro78]

wird der heilige Gral.Es stehen spannende Tage vor uns.

[asuro78]

http://finance.yahoo.com/news/profit-war-obesity-left-dead-1…" target="_blank" rel="nofollow ugc noopener">http://finance.yahoo.com/news/profit-war-obesity-left-dead-1…

[asuro78]

Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.

[asuro78]

us vorbörse 2, 64 $, denke fda ende januar

[asuro78]

FF taxe 2, 00 zu 2, 40 gibt es schon news von der fda?

[asuro78]

Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.

[asuro78]

http://stockcharts.com/h-sc/ui?s=ETRM&p=D&b=5&g=0&id=p127281…" target="_blank" rel="nofollow ugc noopener">http://stockcharts.com/h-sc/ui?s=ETRM&p=D&b=5&g=0&id=p127281…

[asuro78]

kommt heut der ausbruch über 2, 60 ?

[asuro78]

Short Interest (Shares Short)6,426,000Days To Cover (Short Interest Ratio)4.1Short Percent of Float21.19 %Short Interest - Prior4,575,100Short % Increase / Decrease40.46Daily Naked Short Selling ListviewShort Squeeze Ranking™

[asuro78]

http://www.ariva.de/enteromedics-aktie/chart?boerse_id=40&re…" target="_blank" rel="nofollow ugc noopener">http://www.ariva.de/enteromedics-aktie/chart?boerse_id=40&re…

[icebox1977]

Was sagst du zu den Buyout Gerüchten?

[illmatix]

Antwort auf Beitrag Nr.: 46.621.093 von icebox1977 am 13.03.14 11:52:40

ich werd hier heute mal ne kleine posi reinlegen

der chart sieht gut aus

[asuro78]

COUNTDOWN: 6 WEEKS TO APPROVAL

[asuro78]

http://finance.yahoo.com/echarts?s=ETRM+Interactive#symbol=E…

[asuro78]

http://finance.yahoo.com/echarts?s=ETRM+Interactive#symbol=E…

[asuro78]

noch 21 tage

[WeSSaL]

Hallo,
dieses kleine Unternehmen ist hoch interessant.
Nach meinen Unterlagen sollte die Entscheidung über die FDA Zulassung am 29.05.2014 fallen.
Warum kommt es zu dieser Verschiebung, weißt Du Näheres?

Welche Informationsquellen sind dafür seriös bzw. benutzt Du.

Vielen Dank im Voraus und schönes WE

Ciao Sebastian

[icebox1977]

Antwort auf Beitrag Nr.: 47.074.968 von WeSSaL am 30.05.14 14:43:34

http://finance.yahoo.com/mb/forumview/?&bn=3c0b8ac2-a317-336…


verschoben wegen eines Sturm´s zu der Zeit glaub ich.

[dirk3333]

http://seekingalpha.com/article/1168571-enteromedics-vbloc-o…

dieser beitrag ist zwar schon älter , aber ich frage einfach mal keck in die runde was sich seitdem verbessert/verändert hat . ??

weiß da einer was nütziches ?

[leutzsch2001]

EnteroMedics trading halted • 8:47 AM

•The NASDAQ halts trading in EnteroMedics (ETRM) pending news from an Ad Comm meeting to discuss whether or not to recommend regulatory approval for the company's Maestro System for treating morbid obesity.

[icebox1977]

http://stocktwits.com/symbol/ETRM

tweeting live from adcom

[icebox1977]

http://www.smarteranalyst.com/2014/06/18/roth-capital-raises…

[asuro78]

EnteroMedics Announces FDA Advisory Committee Recommendation on VBLOC(R) Vagal Blocking Therapy for the Treatment of Obesity

By Market Wire,  June 17, 2014, 05:24:00 PM EDTVote upAAA

Panel Votes 6 to 2, With 1 Abstention, That Benefits Outweigh Risks

ST. PAUL, MN -- (Marketwired) -- 06/17/14 -- EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) Advisory Gastroenterology and Urology Devices Panel (GUDP) voted 8 to 1 "in favor" that the device is safe when used as designed, and voted 4 to 5 "against" on the issue of a reasonable assurance of efficacy. The final vote, on whether the relative benefits outweighed the relative risk, was 6 to 2 "in favor," with 1 abstention.The FDA is not bound by the GUDP's recommendation, but will take it into consideration when reviewing the Maestro System Premarket Approval (PMA). As previously announced, the Company expects a decision on approval of the PMA later this year. If approved, the Maestro Rechargeable System will be the first new medical device approved for obesity by the FDA in over ten years."Obesity is the most under-treated disease in this country, despite its increasingly well-understood role in co-morbid conditions ranging from hypertension and diabetes to cancer," said Greg Lea, Senior Vice President, Chief Operating Officer and Chief Financial Officer of EnteroMedics, "Where existing options are clearly failing to address the growing epidemic of obesity, we believe VBLOC Therapy may offer a unique approach to treating obesity, a choice that fills this void by offering a safe, reversible option that does not alter the anatomy, allowing patients to take a positive path towards improving their overall health. We thank the Committee members for their insights and look forward to a continued, productive dialogue with the FDA."In the most recent clinical trial, the ReCharge Study, VBLOC Therapy treated patients demonstrated a clinically meaningful and statistically significant excess weight loss (EWL) at 12 months of 24.4%, sustained out to 18 months. The majority (52.5%) lost 20% or more of their excess weight and nearly one-third of VBLOC Therapy treated patients lost 30% or more. The 24.4% average EWL far exceeds the 10% to 15% thresholds at which patients experience substantial positive health effects. Statistically significant improvements were observed in the VBLOC Therapy treatment group in total cholesterol, LDL, triglycerides, systolic and diastolic blood pressure, heart rate and waist circumference.About EnteroMedics Inc.EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses, which helps control both hunger and fullness. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics' Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.Forward-Looking Safe Harbor Statement:This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER™ and ReCharge pivotal trials; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 27, 2014. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.Caution - Investigational device. Limited by Federal (United States) law to investigational use.The implantation procedure and usage of the Maestro® System carry some risks, such as the risks generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical study informed consent.Media Contact: Dan McGinnMcGinn and Company 703-447-8710Read more: http://www.nasdaq.com/press-release/enteromedics-announces-f…

[asuro78]

EnteroMedics Announces Three Year Diabetes, Hypertension and Weight Loss Data from the Maestro® RC System DM2 ENABLE Study
By PR Newswire, August 28, 2014, 07:00:00 AM EDT
Vote up AAA



DM2 ENABLE Study data to be presented today at the 19th Annual Meeting of the International Federation for the Surgery of Obesity and Metabolic Disorders

ST. PAUL, Minn., Aug. 28, 2014 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, announced that three year diabetes, hypertension and weight loss data from the Company's DM2 ENABLE Study of VBLOC® vagal blocking therapy delivered via the Maestro® Rechargeable (RC) System will be presented today at the 19th Meeting of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) being held August 26-30, 2014 in Montreal, Canada. The presentation will be delivered by Scott Shikora, MD, FACS, Associate Professor of Surgery, Harvard Medical School, Director, Center for Metabolic and Bariatric Surgery, Brigham and Women's Hospital and EnteroMedics' Consulting Chief Medical Officer.

"Results from the DM2 ENABLE study of reversible vagal nerve blocking with the implantable Maestro Rechargeable System continue to demonstrate both medically meaningful weight loss as well as improvement in diabetes control in obese subjects with Type II Diabetes Mellitus. Most significantly, the benefits of VBLOC Therapy are sustained through the 36 month follow-up period of the trial with continued excellent overall and cardiovascular safety profiles," said Dr. Shikora. "These data continue to support the widely accepted role of bariatric surgery in the treatment of metabolic disorders."

VBLOC-DM2 ENABLE Study Data

The DM2 Study is an international, open-label, prospective, multi-center study designed to evaluate the safety and efficacy of VBLOC® vagal blocking therapy delivered via the Maestro® RC System in 28 diabetic subjects with obesity by measuring average percentage excess weight loss (EWL), HbA1c (blood sugar), fasting plasma glucose (FPG, blood sugar) and blood pressure, following device activation. To date, no deaths or unanticipated adverse device effects have been reported during the VBLOC-DM2 ENABLE Study and the safety profile is similar to that seen in other VBLOC clinical trials.

At 36 months, HbA1c levels dropped from 7.6% at baseline to 7.0% (p=0.04), which according to the American Diabetes Association, is the reasonable target for many adults with diabetes and has been shown to reduce microvascular complications of diabetes. Furthermore, 83% of the patients who were being treated with one or more diabetic medications at the start of the trial reported no change, a decrease or discontinuation of their medication suggesting that the progression of their diabetes had been modified.

In combination with the HbA1c results, three year fasting plasma glucose (from 155.6 mg/dl at baseline to 131.5 mg/dl (p=0.015)) and excess weight loss of 24.3% (p<0.0001) continue to demonstrate the long-term stability of VBLOC Therapy as both a weight loss and a promising metabolic disease intervention. Of note, the improvement in blood pressure at 36 months (mean arterial pressure -7.3 mm/Hg (p=0.14)) in hypertensive patients was also maintained. These metabolic effects in diabetes, hypertension and weight loss are consistent with previous findings from other time points and are considered medically meaningful improvements.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience-based technology to treat obesity and metabolic diseases. VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses, which helps control both hunger and fullness. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics' Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER™ and ReCharge pivotal trials; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 27, 2014. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution - Investigational device. Limited by Federal (United States) law to investigational use.

The implantation procedure and usage of the Maestro® System carry some risks, such as the risks generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical study informed consent.

SOURCE EnteroMedics Inc.



Read more: http://www.nasdaq.com/press-release/enteromedics-announces-t…

[icebox1977]

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc…

[icebox1977]

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc…

[asuro78]

EnteroMedics Inc. (ETRM) got regulatory approval today for a first-of-its-kind weight-loss device that tricks users into feeling full. Now it has to persuade insurers to cover the gadget’s price tag of at least $15,000.

It’s a tough hurdle. Many insurers and government agencies have refused to cover previous weight-loss treatments, such as Vivus Inc. (VVUS)’s Qsymia and Belviq, by Arena Pharmaceuticals Inc. and Eisai Co. To get a better outcome, EnteroMedics will have to show the device, Maestro Rechargeable System, is safe enough.

Insurance coverage could help EnteroMedics tap a market of 20 million obese patients in the U.S., according to Chief Financial Officer Greg Lea. The Food and Drug Administration approved the system today for obese patients 18 and older who have at least one other weight-related condition, such as Type 2 diabetes -- the first obesity device approved in the U.S. since 2007.

The FDA approval sent shares of EnteroMedics up 19 percent to $1.40 at the close, giving the company a market value of $97 million. The St. Paul, Minnesota-based company, founded in 2002, focuses on regulating the vagus nerve, which controls appetite.

Maestro is currently considered a Category 3 device by the FDA, with insufficient data to receive reimbursement by government agencies. EnteroMedics is pushing to have it classified as safe by next year, which would make private insurers more likely to come aboard, Lea said today in an interview.


Source: EnteroMedics Inc. via Bloomberg
EnteroMedics’ system uses electrodes implanted in the abdomen to send electrical pulses... Read More
“Our strength for the reimbursement path is, one, safety; we have a very strong benefit-versus-risk profile,” Lea said. “We don’t produce a lot of very severe issues with our procedure that create a million-dollar patient.”

Out of Pocket

In the meantime, EnteroMedics will try to introduce the treatment to patients who can pay out-of-pocket and don’t want to wait for insurance approval, Lea said. He estimated that the full price for Maestro, which targets the pathway between the brain and the stomach that controls feelings of hunger, could come in between $15,000 and $30,000. That’s competitive with comparable surgery options, according to Lea.

Maestro is likely to get insurance reimbursement because it fills an important gap, according to Chris Lewis, an analyst at Roth Capital Partners. He’s one of four who recommend buying the stock, while one analyst has a hold rating, according to data compiled by Bloomberg.

“There are a lot of patients in this gap between drugs and exercise and changes in diet, and on the other spectrum is the more invasive bariatric surgical options like Lap-Band,” Lewis said. “This fills that gap.”


Source: EnteroMedics Inc. via Bloomberg
EnteroMedics Inc.'s weight-loss device uses implantable electrodes to trick the brain... Read More
Getting government health agency approval by 2016 is still a “best-case scenario,” Lewis said.

“It’s not going to be a billion-dollar revenue company -- it’s going to take time to get there,” he said.

To contact the reporter on this story: Doni Bloomfield in New York at [e-mail]

To contact the editors responsible for this story: Crayton Harrison at [e-mail] John Lear

[Gento]

Die Zulassung ist da. Sogleich wird gezweifelt, ob Enteromedics bei einer Preisgestaltung beim Gerät incl. chirurgischen Eingriff, vergleichbar mit den Kosten eines Magenbandes (ca. 20.000 bis 30.000$), wirtschaftlichen Erfolg haben wird. Da sollen wohl die Krankenversicherungen noch nicht so begeistert sein. Vielleicht ist dies die Erklärung für den verhaltenen Kursverlauf nach Bekanntgabe der Zulassung des Gerätes.
Jetzt muss sich zeigen, dass Geld verdient wird. Es wäre unlogisch, den Kurs weiter unten zu halten, so als ob die Zulassung noch nicht da wäre.
SELL ON GOOD NEWS. Nachdem alle raus sind, die jetzt unbedingt raus wollen, wird der Kurs langsam steigen.

[Gento]

Canaccord sieht jetzt einen Zielkurs von 4$, Zacks bei 1,60$ andere bei 7$. Ich denke so in der Mitte könnte er sich mittelfristig einpendeln.

[i2fan]

Antwort auf Beitrag Nr.: 48.841.271 von Gento am 21.01.15 18:14:40

nur der Kursverlauf passt nicht zu den Kurszielen.

[icebox1977]

mal sehen ob die Versicherungen sich an der Therapie beteiligen, sollte da der Fall sein können wir mit steigenden Kursen rechnen, ich finde die Technik toll und gebe dem ganzen die nötige Zeit!

[Gento]

Warum der Kurs so niedrig ist? Es gibt Kommentare, dass es für Enteromedics Konkurrenz gibt. So erhielten schon vor Enteromedics drei Anbieter von Abnehmpillen ebenfalls die FDA-Zulassung. Ausserdem wird der Abnehmeffekt bei Enteromedics kritisiert. Und dass Enteromedics zur Einführung seines Produktes vermutlich weiteres Geld eintreiben muss.

Andererseits sind (oder waren, die neusten Zahlen sind noch nicht ersichtlich) einige stark short engagiert. Die Shorties hätten ein Interesse, dass der Wert noch ein wenig gedrückt wird, was auch gelingen kann, solange o.g. Bedenken von Enteromedics nicht zerstreut werden können.

Es kann alles in allem ein holpriger Start werden. Aber vielleicht soll dieser Eindruck auch absichtlich entstehen.

Ich kann mir nur schwer vorstellen, dass Enteromedics langfristig scheitern wird. Die Technik kommt dem natürlichen Abnehmen sehr Nahe. Es gibt keinen so schweren Eingriff wie beim Magenband. Pillen greifen ebenfalls auf unnatürlicher Art und Weise in den Stoffwechsel ein, verbunden mit Nebenwirkungen wie Stoffwechselstörungen und Mangelerscheinungen.

Wenn Patienten alle Vor- und Nachteile kennen, werden sich viele für die VBLOC-Therapie entscheiden.

Die Frage ist nur, wann Enteromedics damit schwarze Zahlen schreibt.

[icebox1977]

Antwort auf Beitrag Nr.: 48.894.995 von Gento am 27.01.15 11:51:15

toller Komentar!
Sehe das genaus so und der Faktor Zeit ist halt wichtig und wer keine hat der verabschiedet sich halt aus dem Investment!

[Gento]

Cannacord hat nach der Veröffentlichung der Quartalszahlen sein Kursziel von 4$ bekräftigt. Es war ein leicht besseres Ergebnis als erwartet.

Trotzdem hatten Investoren ihre Shortpositionen erhöht. Dies scheint nun den Aktienpreis unter Druck zu halten.

Da muss sich jemand seiner Sache sehr sicher sein, dass er trotz FDA Zulassung und trotz optimistischer Analystenkommentare auf ein weiteres Fallen der Kurse spekulieren kann. Und dies scheint auch zu funktionieren. Es sind derzeit 7,85 Mio Aktien short verkauft worden. Diese müssen irgendwann alle wieder zurückgekauft werden. Zur Zeit werden etwa 1 Mio Aktien pro Tag gehandelt. Das würde bedeuten, dass 7-8 Tage lang Aktien gekauft werden müssten, ohne dabei den Preis hochzutreiben. Das geht nur bei Resignation und Panik der Anleger, wenn viele ihre Aktien auf dem Markt ausschütten.
Vielleicht will man den Preis unter die alten Tiefs drücken um die ersehnte Lawine loszutreten.

Sollte dieses Vorhaben scheitern, könnte es zu einem sehr schnellen Anstieg kommen.

[Gento]

Es wurde begonnen Shortpositionen abzubauen(-12%). Es sind aber noch immer über 7 Millionen Aktien leer verkauft, macht 12 % der Gesamtanzahl der öffentlichen Aktien. Genug für einen ordentlichen Short Squeeze.

Oder kommt es noch zu einer Ausverkaufswelle? Denn die letzte war ja keine mit den geringen Umsätzen.

Es sind auch bereits viele Institutionelle mit einer gewissen Marktmacht drin. Ob die das Spiel nach unten noch einmal mitmachen wollen?

Abwarten.

[icebox1977]

Erstes kommerzielles Implantat

http://www.smarteranalyst.com/2015/05/20/company-update-nasd…

[asuro78]

http://m.wcvb.com/health/tufts-patient-first-to-get-new-high…

[asuro78]

Kevin Douglas changes stake to active at EnteroMedics ($ETRM)
Posted By: activiststocksPosted date: May 27, 2015 10:04:12 PMIn: StocksNo Comments
Kevin Douglas owns 14.2% of the $100mm market cap medical device company. He’s owned shares for over half a decade, but recently decided to go active, here’s why:

The Filers acquired their shares of Common Stock for investment purposes because
they believed the Common Stock represented an attractive investment. However, they may at any time and from time to time determine to seek to contact the Issuer regarding means of increasing stockholder value.



Prior to the date hereof, the Filers had on file with the Securities and Exchange Commission a Schedule 13G with respect to their beneficial ownership of Common Stock, initially filed with the SEC on December 17, 2010. The Filers are filing this Schedule 13D in order to remove any possible impediment to contacting the Issuer regarding means of increasing stockholder value.

[Gento]

Das ist doch mal ein Aderlass. Der Grund ist zwar schlecht, Verwässerung, aber mal schauen, ob die Shortposition heute abgebaut werden konnten. Umsatz war (ist) ja da.
Respekt für die Shorties, die müssen Insider sein und gewusst haben, dass Enteromedics sich noch einmal Geld in Größenordnungen beschaffen muss und damit der Kurs in die Knie gehen wird, Meldung dazu siehe heute. Die haben aber auch bisher beharrlich Ihre Positionen gehalten.
War es das jetzt?
Im Endeffekt ist die zusätzliche Geldbeschaffung gut, es kann somit schneller der Switch in höhere Umsatzklassen erreicht werden. Das sollte sich auch bald im Kurs widerspiegeln.
Ist das jetzt eine Kaufgelegenheit? Muss jeder selber entscheiden.

[Gento]

Hier noch die Meldung von heute:

homeRecent News
EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants
« Previous Releases
ST. PAUL, Minn., June 30, 2015 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), a developer and manufacturer of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, announced the pricing of its previously announced public offering of 40,229,886 units. Each unit consists of one share of common stock, 0.50 of a Series A warrant to purchase one share of common stock, and 0.50 of a Series B warrant to purchase one share of common stock, at a purchase price of $0.87 per unit. Investors whose purchase of units in the offering would result in them beneficially owning more than the initial beneficial ownership limitation to be included in the warrants following the consummation of the offering will have the opportunity to acquire units with Series C pre-funded warrants substituted for any common stock they would have otherwise acquired over the initial beneficial ownership limitation, paying the same price of $0.87 per unit. The Series A warrants will be exercisable immediately and will expire three years following issuance at an exercise price of $1.00 per share. The Series B warrants will be exercisable immediately and will expire 12 months following issuance at an exercise price of $1.09 per share. The pre-funded Series C warrants will be exercisable immediately and will expire five years following issuance.

Canaccord Genuity is acting as sole book-running manager and Craig-Hallum Capital Group is acting as co-manager for the offering. Northland Securities and Roth Capital Partners served as financial advisors to the Company in connection with this transaction.

The offering is expected to close on or about July 6, 2015, subject to customary closing conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approvals of the NASDAQ Capital Market.

Net proceeds from the offering are expected to be approximately $32.6 million, after deducting underwriting commissions and other expenses related to the offering. The company intends to use the net proceeds from the offering to continue its commercialization efforts in the United States and internationally, for clinical and product development activities and for other working capital and general corporate purposes

The offering is being made pursuant to a shelf registration statement (File No. 333-195855) previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying base prospectus related to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying base prospectus can be obtained through the website of the SEC at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying base prospectus may also be obtained by contacting the Syndicate Department of Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone/email at [phone]/[e-mail].

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' Maestro Rechargeable System has received U.S. Food and Drug Administration approval, CE Mark and is listed on the Australian Register of Therapeutic Goods.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expectations of EnteroMedics regarding the completion of the registered direct offering. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Actual results and the timing of events may vary materially from those expressed or implied by such forward-looking statements due to various important factors, including, without limitation, risks and uncertainties related to the business of EnteroMedics and the satisfaction of the closing conditions of the registered direct offering. More detailed information about those factors is set forth in the filings of EnteroMedics with the Securities and Exchange Commission, including its annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. EnteroMedics is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enteromedics-inc-ann…

SOURCE EnteroMedics Inc.

News Provided by Acquire Media

© 2015 EnteroMedics Inc.
iPhone Investor Home | View Complete IR Website

[i2fan]

Antwort auf Beitrag Nr.: 50.085.510 von Gento am 30.06.15 21:39:41

war keine Kaufgelegenheit, denn es ging am 02.07.
noch mal heftig nach unten.

[i2fan]

Antwort auf Beitrag Nr.: 50.106.198 von i2fan am 03.07.15 14:31:19

und heute nochmal rund 35 % in rot

[Gento]

Ist schon stark, was hier mit dem Kurs passiert. Die Info, ob die Shorties damit auch raus sind, fehlt mir noch.
Ich konnte bisher auch keine Änderung der Analystenmeinungen zu ETRM lesen. D.h. das Kursziel im Median ist noch immer zwischen 3$ und 4$.
Wie war das mit dem Hund (Börse) und dem Herrchen (Wirtschaft) (v. Kostolany), mal läuft der Hund vor und mal (momentan wohl sehr weit) hinter dem Herrchen.

Eine Verwässerung des Kapitals ändert hier nichts an den vielversprechenden Aussichten für ETRM.
Aber besch.... ist das schon.

[Gento]

4,54 Mio Aktien sind noch immer short (15.07.2015). Es gab nur eine geringe Bereinigung um ca. 30%. Ich hätte 100 % erwartet.

Es geht derzeit eine Angst zum Delisting an der Nasdaq um und drückt auf den Kurs. Ich denke, die Shorties spekulieren jetzt auf ein Re-Splitting, damit ETRM wieder über 1$ kommt, um an der Nasdaq zu bleiben. Soetwas ist immer schlecht für das Image und den Kurs.

Canaccord hat sein Kursziel gesenkt auf 2,50$ von 4$. Damit wäre ich momentan sehr zufrieden.

[Schaeffi]

Canaccord Genuity Reaffirms Buy Rating for EnteroMedics (ETRM) Posted on July 21, 2015 by...

und nochmal weiter runter mit dem Kursziel...


http://sleekmoney.com/canaccord-genuity-reaffirms-buy-rating…
EnteroMedics logoEnteroMedics (NASDAQ:ETRM)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity in a report issued on Tuesday, Market Beat reports.

A number of other firms have also recently commented on ETRM. Analysts at Craig Hallum lowered their price target on shares of EnteroMedics from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Monday. Separately, analysts at Zacks upgraded shares of EnteroMedics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 1st.

EnteroMedics (NASDAQ:ETRM) traded down 7.9682% on Tuesday, hitting $0.3361. 1,229,681 shares of the company’s stock traded hands. EnteroMedics has a 1-year low of $0.33 and a 1-year high of $2.05. The stock’s 50-day moving average is $0.85 and its 200-day moving average is $1.05. The company’s market cap is $25.01 million....



es gibt hier, denk ich rel. viel potentielle Konkurenz und Unsicherheiten noch:

- GSK, Medtronic, Stimwave, CVRx, MicroTransponder,...

- die Probanden der PlaceboGruppe nahmen nur 8,5% weniger ab ,als die Stimulationsgruppe, diese nahmen 25% ab, aber es könnte Anzeichen dafür geben das langfritstig pos. Auwirkungen auf Diabetes bestehen.

Spannendes Thema, die Elektrozeutika

GSK investiert 50 Mio
das US Sparc Programm 250 Mio

Es wird sich zeigen, wo die Reise hingeht!
Bin nicht investiert, aber Watchlist

Krus erinnert mich irgendwie an Aeterna und die reicht mir schon voll und ganz

Gruss S.

[Gento]

Trotz Kurszielsenkungen von Analysten ist das Steigerungspotezial, z.B. 1,25$ vom jetzigen Stand erheblich. Gute Aussichten wären dazu recht hilfreich.


Roth Capital decreased their target price on shares of EnteroMedics (NASDAQ:ETRM) from $2.25 to $1.25 in a research note issued to investors on Friday, StockTargetPrices.com reports. The firm presently has a “buy” rating on the medical device company’s stock. Roth Capital’s price target indicates a potential upside of 393.88% from the company’s previous close.

EnteroMedics (NASDAQ:ETRM) traded down 11.1618% on Friday, hitting $0.2531. The stock had a trading volume of 1,340,802 shares. EnteroMedics has a 52-week low of $0.25 and a 52-week high of $2.05. The company’s 50 day moving average price is $0.51 and its 200 day moving average price is $0.96. The firm’s market cap is $18.83 million.

EnteroMedics (NASDAQ:ETRM) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, hitting the analysts’ consensus estimate of ($0.10). Analysts expect that EnteroMedics will post ($0.35) EPS for the current year.

A number of other equities research analysts have also issued reports on the company. Zacks raised shares of EnteroMedics from a “sell” rating to a “hold” rating in a report on Wednesday, July 1st. Craig Hallum lowered their price target on shares of EnteroMedics from $5.00 to $2.00 and set a “buy” rating for the company in a report on Monday, July 20th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $2.50 price objective (down previously from $4.00) on shares of EnteroMedics in a research note on Tuesday, July 21st.

[Gento]

Canaccord analyst William Plovanic weighed in today with an optimistic view on EnteroMedics Inc (NASDAQ:ETRM), following the company’s recent second-quarter results and a presentation at the Canaccord Global Growth Conference. The analyst maintained a Buy rating on shares of ETRM with a $2.50 price target, which implies an upside of 1119% from current levels.

Plovanic wrote, “We are encouraged by the initial commercialization progress with 51 centers certified and 77 surgeons trained on the procedure. These metrics are tracking ahead of management guidance and our expectations which called for 30 certified sites by YE2015 previously. Additionally, EnteroMedics provided color regarding its DTC campaigns and educational webinars to drive patients to vBloc Therapy. Lastly, EnteroMedics has expanded access to the procedure through financing options and reimbursement support.”

“Net, net we are encouraged by the early commercialization progress and believe the strong physician adoption shows that there is broad interest from physicians and bariatric centers to incorporate vBloc as a treatment option for bariatric patients,” the analyst added.

[Gento]

Was zur Zeit gar nicht passt, sind die mehrfach kommunizierten Analystenziele von z.b. 2-3 $ und der momentane Kurs. Der Kurs scheint wie blockiert. Dazu das noch immer fast unveränderte short interest von über 4 Millionen Aktien bei einem Preis von 0,27$??? Hier gab es schon mehrfach die Möglichkeit, die Shortpositionen gewinnbringend aufzulösen.

Hier stimmt was nicht.

Dann die Tatsache, dass der Marktwert mit 30 Mio unter den Mindestanforderungen der Nasdaq von 35 Mio liegt. Die Differenz von 5 Mio ist eigentlich ein Klacks. Da mann aber gerade die Ziele für 2015 korrigieren musste, vielleicht doch kein Klacks.
Ich frage mich, warum der Marktwert gerade unter die 35 Mio gerutscht ist. Absicht? Steckt da ein Konkurrent dahinter, der ETRM keinen Erfolg gönnt? Den Marktwert unter 35 Mio zu halten, und damit für ein Delisting zu sorgen, wäre für einen grossen Player bei diesem negativen Flow ein Leichtes. (Natürlich nur meine subjektive Vermutung.)

Hier kann kurzfristig nur noch helfen: gute Meldungen und gute Zahlen. Der Quartalsbericht im November muss überzeugen.

http://ir.enteromedics.com/secfiling.cfm?filingID=1193125-15…

[Gento]

Der Kurs wird heute wieder gen Süden "gemalt". Leider scheint von ETRM nichts zu kommen, was Käufer anlocken könnte.

[Gento]

Nun ist ersichtlich, warum der Kurs wie blockiert zu sein scheint. Das short interest hat sich wieder dramatisch auf ca. 7 Mio erhöht und das bei 0,26 $.
Hier sieht man wohl noch erhebliches Potential nach unten. Vermutlich wird für den Quartalsbericht im November ein sehr schlechtes Ergebnis erwartet.
Leider muss man sagen, dass ETRM den Eindruck macht, dass sich diese Vermutungen bestätigen könnten. Es kommen einfach keine Nachrichten zu Erfolgen im Verkauf oder sonst irgendetwas.

Ich hoffe trotzdem auf Überraschungen, welche die shorties zu Eindeckungen zwingen. Ein Großteil der Leerverkäufe dürfte ja nun auf dem Niveau von unter 0,30$ getätigt worden sein. Das könnte auch schnell zu Verlusten führen.
Wir sitzen hier auf einem Pulverfass, nur die Lunte brennt noch nicht.

[Gento]

Der Kurs will in Richtug 0,30$. Da der Shorter (in anderen Boards wird von einem einzigen Investor erzählt) ja etwa bei diesem Niveau nochmal ein paar Mio leerverkauft haben muss, hat er heute wohl das Flattern bekommen. In den letzten Minuten wurde der Kurs gewaltsam von 0,27$ auf unter 0,24$ gedrückt mit bis zu 50k.
Am Ende steht der Kurs aber doch noch bei 0,26$. Hier hält jemand dagegen. Gut so.

Der Quartalsbericht wird zeigen, ob der Shorter hier diesmal auch mit Gewinn herauskommt.

[i2fan]

Antwort auf Beitrag Nr.: 50.973.804 von Gento am 30.10.15 21:30:40

hier kommt jeder mit Gewinn raus.

[Gento]

Habe hier einen Beitrag gefunden, der die Situation für ETRM möglicherweise gut beschreibt.
ETRM braucht Geld, weil die eigenen Einnahmen aus dem Verkauf wohl nicht reichen. Der Reverse-Split wird auch kommen. Es scheint ein langer Weg zu werden, Ausgang offen.

Spencer Osborne, seekingalpha.com
Summary
Enteromedics offering $25 million in convert notes.
Shareholders must approve a reverse split for deal to happen.
Reverse split needed to gain NASDAQ compliance.
Enteromedics (NASDAQ:ETRM) is trying to solve two big overhangs in one fell swoop. The company announced a $25 million direct offering which supplies much needed cash and will also be holding a special shareholder meeting to bring the matter of a reverse split to the shareholders for voting and approval.
Enteromedics has suffered from a slow launch of its vBloc anti-obesity device called the Maestro Recharge System. A slow launch combined with low cash has seen the equity fall below the $1 threshold for remaining in compliance with NASDAQ standards. A reverse split would help the company gain compliance.
I have been critical of three dynamics associated with Enteromedics. The first dynamic is the lack of cash. Low cash has put the company in a poor negotiating position. The second was the framing of expectations. The company allowed investors to make bold assumptions on how widely adopted the Maestro device would be and ultimately set itself up to disappoint the street. Lastly, the company wound up in a position of essentially admitting that a reverse split was the only viable way to gain NASDAQ compliance.
Allow me to keep this very simple. If sales had any indication of a quick uptake at any point in the near future, the need to raise cash by taking on debt at 7% interest and having institutions dictate a shareholder vote on a reverse split would never be needed. This latest transaction is simply further indication that the process of getting any meaningful sales levels out of Maestro will be painfully slow.
What investors need to consider is this. $25 million in notes at $0.29 per share will effectively be dilution of 86.2 million shares. This is on top of a dilution earlier this year of 40 million shares. 6 months ago this company had 75 million shares outstanding. Should the current proposal go through, the share count could be as high as 201 million.
A reverse split by a factor of 10 would lower the share count to about 20 million and raise the share price to about $2.90. The big problem with all of this is that the underlying issues surrounding Maestro and sales still exist. Shareholders will now be saddled with additional dilution, a reverse split, and then revenue prospects that will have the company needing cash yet again in the near term.
In simple terms, the challenges for this company are not going away any time soon. While an infusion of $25 million will help kick the proverbial can down the road, it will not likely be enough to get the company to the promised land. As I projected months ago, the delisting process was not going to make life easy for this company, and a poor cash position forced this company to negotiate from weakness rather than strength.
These dynamics are not an indictment on the Maestro device. It has a place in the market. The biggest issue is that it takes a lot of cash and muscle to bring a new medical device to the mainstream and this company is lacking in both areas. Could Enteromedics be bought out? Sure. Just remember this though. The company is still negotiating from a point of weakness. The most likely benefactors in a buyout would be the acquiring company shareholders and not ETRM shareholders. Stay Tuned!

[Gento]

Was für ein Triumph für den Shorter. Von 1,50$ bis 0,15$ leerverkauft, das nenne ich Performance.
Der muss Insiderwissen haben. Mark B. Knudson? Nein, sicher nicht.
Der Shorter muss um die Finanzierungslücken gewusst haben. Und das mit einer erstaunlich hohen Ausdauer und Treffsicherheit. Sehr verdächtig.

Der Quartalsbericht gibt auch keine große Hoffnung auf einen schnellen Trendwechsel.

[raphel]

Hallo,

ist hier noch jemand dabei? Neue WKN:US29365M5058
Ist hier wiede etwas im Busch???
Wer hat Infos??

[H2OAllergiker]

Beobachte die Aktie schon länger. Volker Michler vom Z10 Investor empfiehlt momentan eine Aktie, die Fettleibigkeit bekömpfen soll, da kommt für mich nach de Zulasssung von VBLOC nurmerh ETRM in Frage. Bin allerdings kein Biotechexperte wie andere. Der jüngste Anstieg war einer der gewaltigsten, den ich in so kurzer Zeit je gesehen habe 3000% in nichtmal 3 Monaten? Oder hatte das was mit der Aktien-Umstrukturierung zu tun gehabt?

[Schif]

Was für ein Triumph für den Shorter. Von 1,50$ bis 0,15$ leerverkauft, das nenne ich Performance.
von Gento im Jahre 2015

gestern das gleiche spielchen, oder die Firma ist Pleite ??

[herku]

Ist das nun die Bodenbildung oder das Ende? Wahnsinn wie man das Teil runter gebracht hat.